The CAVΛDIS™ pipeline contains a series of novel biomarkers in various phases of development. Individual markers and multi-marker panels are selected for developing prognostic tests for cardiovascular indications, including myocardial infarction (MI), stroke, and peripheral artery disease (PAD).
CAVΛDIS™ developed an innovative approach to screen for biomarkers of progressive atherosclerotic disease. This approach of assessing protein expression linked to hard clinical endpoints has led to the discovery of a series of novel biomarkers in plasma and atherosclerotic vessel wall tissue. The predictive power of these biomarkers outperforms traditional risk factors.
The diagnostic and prognostic power of selected high-potential biomarkers for cardiovascular events is being validated in large primary and secondary prevention cohorts. These validation efforts will lead to the development of CAVΛRISK ASSAYS™. Current focus is on CAVΛRISK CΛD™, a blood-based prognostic assay to identify patients at risk of coronary artery disease (CAD). In addition, multiple other applications (diagnostic, surrogate marker of efficacy, therapeutic target) are screened in collaboration with our industry partners.
- CAVΛDIS™ discovered a series of novel cardiovascular biomarkers.
- CAVΛRISK ASSAYS™ are being developed for cardiovascular indications.
- CAVΛRISK CΛD™ will be specifically developed for coronary artery disease (CAD).
DIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. The company's mission is to identify patients at risk of developing heart attacks and strokes. Our ultimate goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.